Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

about

Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

Item

http://www.wikidata.org/entity/Q41670908

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Reduced Cytokine Release in Ex ...... Head and Neck Cancer Patients

@en

type

Item

label

Reduced Cytokine Release in Ex ...... Head and Neck Cancer Patients

@en

prefLabel

Reduced Cytokine Release in Ex ...... Head and Neck Cancer Patients

@en

P1476

Reduced Cytokine Release in Ex ...... Head and Neck Cancer Patients

@en

P2093

Andreas Dietz

http://www.w3.org/2001/XMLSchema#string

Gunnar Wichmann

http://www.w3.org/2001/XMLSchema#string

Susan Cedra

http://www.w3.org/2001/XMLSchema#string

Susanne Wiegand

http://www.w3.org/2001/XMLSchema#string

P2860

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

RGD-Binding Integrins in Head and Neck Cancers.

Cytokine patterns in patients with cancer: a systematic review.

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.

Monocyte chemotactic protein 1 (MCP-1) modulates pro-survival signaling to promote progression of head and neck squamous cell carcinoma.

Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.

Monocyte chemoattractant protein-1 (MCP-1): an overview

P31

scholarly article

P356

10.3390/CANCERS9090117

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marlen Kolb

P577

2017-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28872582

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab

P932

5615332

http://www.w3.org/2001/XMLSchema#string